Abstract: Subject-matter of the present invention is an array comprising soaking solutions for soaking a biological macromolecular crystal. Further, the subject of the invention is a rule-based method of selecting specific soaking solution compositions having a specific composition comprising composite solute(s), water (w), crystallization solution (crs) and/or organic solvent(s). Additionally, the subjects matter of the invention the soaking solutions obtained by the method of the invention and a screening method for small molecules comprising molecular probes, fragments and drug-size molecules using the soaking solutions and the use of the soaking solutions in a screening method for small molecules on a macromolecular crystal.

Abstract: Subject-matter of the present invention is an array comprising soaking solutions for soaking a biological macromolecular crystal. Further, the subject of the invention is a rule-based method of selecting specific soaking solution compositions having a specific composition comprising composite solute(s), water (w), crystallization solution (crs) and/or organic solvent(s). Additionally, the subjects matter of the invention the soaking solutions obtained by the method of the invention and a screening method for small molecules comprising molecular probes, fragments and drug-size molecules using the soaking solutions and the use of the soaking solutions in a screening method for small molecules on a macromolecular crystal.

Abstract: The present invention relates to crystal forms of blood coagulation factor XIIIa, crystal structure information obtained from them, methods of preparing such crystal forms, their use for the identification and/or design of inhibitors of blood coagulation factor XIIIa activity and methods for identifying, optimizing and designing compounds which should have the ability to interact with or inhibit blood coagulation factor XIIIa.

Abstract: The present invention concerns substances which act as selective ligands of nuclear receptors of the PPAR beta/delta subtype and which can be used for the treatment of PPAR beta/delta-mediated diseases. The substances of this invention act as inhibitors of PPAR beta/delta receptors.

Abstract: The invention relates to a lipase variant which can be prepared by carrying out, on the amino acid sequence of a starting lipase selected from the lipase homologous family I.1 or I.2, at least one amino acid substitution in those positions which correspond to the positions 17, 29, 30, 52, 86, 117, 122, 160, 163, 167, 265, 266, 286, 289 in the prototype lipase sequence SEQ ID NO: 1.

Abstract: The invention relates to a lipase variant which can be prepared by carrying out, on the amino acid sequence of a starting lipase selected from the lipase homologous family I.1 or I.2, at least one amino acid substitution in those positions which correspond to the positions 17, 29, 30, 52, 86, 117, 122, 160, 163, 167, 265, 266, 286, 289 in the prototype lipase sequence SEQ ID NO: 1.

Abstract: Sulfonamides of the general formula I ##STR1## where A, n, R.sup.1, R.sup.2, R.sup.3, W, X, Y and Z have the meanings given in the disclosure and claims, salts and N-oxides thereof, and their use as herbicidal agents.

Abstract: Sulfonamides of the general formula I ##STR1## where A, n, R.sup.1, R.sup.2, R.sup.3, W, X, Y and Z have the meanings given in the disclosure and claims, salts and N-oxides thereof, and their use as herbicidal agents.

Abstract: Sulfonamides of the general formula I ##STR1## where A, n, R.sup.1, R.sup.2, R.sup.3, W, X, Y and Z have the meanings given in the disclosure and claims, salts and N-oxides thereof, and their use as herbicidal agents.